
Guillermo L Virkel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2564314/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Combination of cypermethrin and thymol for control of Rhipicephalus microplus: Efficacy evaluation and description of an action mechanism. Ticks and Tick-borne Diseases, 2022, 13, 101874.	2.7	14
2	Metabolic stability of glyphosate and its environmental metabolite (aminomethylphosphonic acid) in the ruminal content of cattle. Food Additives and Contaminants - Part A Chemistry, Analysis, Control, Exposure and Risk Assessment, 2022, , 1-12.	2.3	1
3	<i>In vitro</i> inhibition of the hepatic S-oxygenation of the anthelmintic albendazole by the natural monoterpene thymol in sheep. Xenobiotica, 2020, 50, 408-414.	1.1	12
4	Combination of bioactive phytochemicals and synthetic anthelmintics: In vivo and in vitro assessment of the albendazole-thymol association. Veterinary Parasitology, 2020, 281, 109121.	1.8	14
5	In vitro and in vivo effects of chlorpyrifos and cypermethrin on blood cholinesterases in sheep. Journal of Veterinary Pharmacology and Therapeutics, 2019, 42, 548-555.	1.3	2
6	Effects of fenbendazole and triclabendazole on the expression of cytochrome P450 1A and flavin-monooxygenase isozymes in bovine precision-cut liver slices. Veterinary Journal, 2019, 245, 61-69.	1.7	6
7	Oxfendazole kinetics in pigs: In vivo assessment of its pattern of accumulation in Ascaris suum. Experimental Parasitology, 2019, 199, 52-58.	1.2	7
8	Role of ABC Transporters in Veterinary Medicine: Pharmaco- Toxicological Implications. Current Medicinal Chemistry, 2019, 26, 1251-1269.	2.4	27
9	Pharmacokinetic assessment of the monepantel plus oxfendazole combined administration in dairy cows. Journal of Veterinary Pharmacology and Therapeutics, 2018, 41, 292-300.	1.3	6
10	Strategies to Optimize the Efficacy of Anthelmintic Drugs in Ruminants. Trends in Parasitology, 2018, 34, 664-682.	3.3	82
11	Species differences in hepatic biotransformation of the anthelmintic drug flubendazole. Journal of Veterinary Pharmacology and Therapeutics, 2017, 40, 493-499.	1.3	8
12	Assessment of liver slices for research on metabolic drug–drug interactions in cattle. Xenobiotica, 2017, 47, 933-942.	1.1	4
13	Hepatic biotransformation pathways and ruminal metabolic stability of the novel anthelmintic monepantel in sheep and cattle. Journal of Veterinary Pharmacology and Therapeutics, 2016, 39, 488-496.	1.3	7
14	The herbicide glyphosate is a weak inhibitor of acetylcholinesterase in rats. Environmental Toxicology and Pharmacology, 2016, 45, 41-44.	4.0	33
15	Comparative pharmacokinetic and pharmacodynamic response of single and double intraruminal doses of ivermectin and moxidectin in nematode-infected lambs. New Zealand Veterinary Journal, 2015, 63, 227-234.	0.9	17
16	Effects of Sublethal Exposure to a Glyphosate-Based Herbicide Formulation on Metabolic Activities of Different Xenobiotic-Metabolizing Enzymes in Rats. International Journal of Toxicology, 2014, 33, 307-318.	1.2	28
17	In vitro and in vivo assessment of the benzydamine-mediated interference with the hepatic S-oxidation of the anthelmintic albendazole in sheep. Small Ruminant Research, 2014, 120, 142-149.	1.2	5
18	A pharmacology-based comparison of the activity of albendazole and flubendazole against Echinococcus granulosus metacestode in sheep. Acta Tropica, 2013, 127, 216-225.	2.0	24

Guillermo L Virkel

#	Article	IF	CITATIONS
19	Effects of sub-lethal exposure of rats to the herbicide glyphosate in drinking water: Glutathione transferase enzyme activities, levels of reduced glutathione and lipid peroxidation in liver, kidneys and small intestine. Environmental Toxicology and Pharmacology, 2012, 34, 811-818.	4.0	82
20	Expression differential of microsomal and cytosolic glutathione-S-transferases in Fasciola hepatica resistant at triclabendazole. Molecular and Biochemical Parasitology, 2012, 181, 37-39.	1.1	22
21	Characterization of xenobiotic metabolizing enzymes in bovine small intestinal mucosa. Journal of Veterinary Pharmacology and Therapeutics, 2010, 33, 295-303.	1.3	12
22	Phase 1 and phase 2 metabolic activities along the small intestine in adult male sheep1. Journal of Veterinary Pharmacology and Therapeutics, 2010, 33, 537-545.	1.3	7
23	Combined use of ivermectin and triclabendazole in sheep: In vitro and in vivo characterisation of their pharmacological interaction. Veterinary Journal, 2009, 182, 261-268.	1.7	26
24	Enantiomeric behaviour of albendazole and fenbendazole sulfoxides in domestic animals: Pharmacological implications. Veterinary Journal, 2009, 181, 241-250.	1.7	41
25	Albendazole enantiomeric metabolism and binding to cytosolic proteins in the liver fluke Fasciola hepatica. Veterinary Research Communications, 2009, 33, 163-173.	1.6	16
26	Inhibition of cytochrome P450 activity enhances the systemic availability of triclabendazole metabolites in sheep. Journal of Veterinary Pharmacology and Therapeutics, 2009, 32, 79-86.	1.3	21
27	Evaluation of the interaction between ivermectin and albendazole following their combined use in lambs. Journal of Veterinary Pharmacology and Therapeutics, 2008, 31, 230-239.	1.3	37
28	Hepatic and extra-hepatic metabolic pathways involved in flubendazole biotransformation in sheep. Biochemical Pharmacology, 2008, 76, 773-783.	4.4	43
29	Understanding triclabendazole resistance. Experimental and Molecular Pathology, 2007, 82, 104-109.	2.1	195
30	Assessment of the main metabolism pathways for the flukicidal compound triclabendazole in sheep. Journal of Veterinary Pharmacology and Therapeutics, 2006, 29, 213-223.	1.3	52
31	Moxidectin and ivermectin metabolic stability in sheep ruminal and abomasal contents. Journal of Veterinary Pharmacology and Therapeutics, 2005, 28, 411-418.	1.3	24
32	COMPARATIVE HEPATIC AND EXTRAHEPATIC ENANTIOSELECTIVE SULFOXIDATION OF ALBENDAZOLE AND FENBENDAZOLE IN SHEEP AND CATTLE. Drug Metabolism and Disposition, 2004, 32, 536-544.	3.3	74
33	Integrated pharmacological assessment of flubendazole potential for use in sheep: disposition kinetics, liver metabolism and parasite diffusion ability ¹ . Journal of Veterinary Pharmacology and Therapeutics, 2004, 27, 299-308.	1.3	35
34	Effect of the ionophore antibiotic monensin on the ruminal biotransformation of benzimidazole anthelmintics. Veterinary Journal, 2004, 167, 265-271.	1.7	9
35	Triclabendazole biotransformation and comparative diffusion of the parent drug and its oxidized metabolites intoFasciola hepatica. Xenobiotica, 2004, 34, 1043-1057.	1.1	50
36	Effect of amphiphilic surfactant agents on the gastrointestinal absorption of albendazole in cattle. Biopharmaceutics and Drug Disposition, 2003, 24, 95-103.	1.9	7

Guillermo L Virkel

#	Article	IF	CITATIONS
37	In vitro ruminal biotransformation of benzimidazole sulphoxide anthelmintics: enantioselective sulphoreduction in sheep and cattle. Journal of Veterinary Pharmacology and Therapeutics, 2002, 25, 15-23.	1.3	31
38	Albendazole sulphoxide enantiomeric ratios in plasma and target tissues after intravenous administration of ricobendazole to cattle. Journal of Veterinary Pharmacology and Therapeutics, 2001, 24, 117-124.	1.3	26
39	Enantioselective liver microsomal sulphoxidation of albendazole in cattle: effect of nutritional status. Xenobiotica, 2000, 30, 381-393.	1.1	11
40	Enantioselective liver microsomal sulphoxidation of albendazole in cattle: effect of nutritional status. Xenobiotica, 2000, 30, 381-393.	1.1	7
41	Influence of diet on the pattern of gastrointestinal biotransformation of netobimin and albendazole sulphoxide in sheep. European Journal of Drug Metabolism and Pharmacokinetics, 1999, 24, 31-37.	1.6	12